We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Awarded by the Biomedical Advanced Research and Development Authority (BARDA), the new contract also includes the company’s planned Phase III development programme for ridinilazole.